How many drugs treat Mixed hyperlipidemia?

Drug Landscape tracks 10 marketed treatments for Mixed hyperlipidemia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/mixed-hyperlipidemia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Mixed hyperlipidemia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mixed hyperlipidemia (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Mixed hyperlipidemia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Livalo	PITAVASTATIN	Kowa Co	HMG-CoA Reductase Inhibitor	3-hydroxy-3-methylglutaryl-coenzyme A reductase	2009-01-01
Trilipix	CHOLINE FENOFIBRATE	AbbVie	Peroxisome Proliferator Receptor alpha Agonist	Fatty acid-binding protein, intestinal	2008-01-01
Crestor	rosuvastatin	AstraZeneca	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	2003-01-01
Zetia	EZETIMIBE	Merck & Co.	HMG-CoA Reductase Inhibitor [EPC]	Niemann-Pick C1-like protein 1	2002-01-01
Baycol	CERIVASTATIN	Bayer	cerivastatin	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1997-01-01
Lipitor	atorvastatin	Pfizer Inc.	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	1996-12-17
Lipitor	Atorvastatin Calcium	Pfizer	atorvastatin	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1996-01-01
Tricor (Micronized)	FENOFIBRATE	Salix	Peroxisome Proliferator Receptor alpha Agonist [EPC]	PPARα	1993-01-01
Lescol	FLUVASTATIN	Novartis	HMG-CoA Reductase Inhibitor	HMG-CoA reductase	1993-01-01
Mevacor	LOVASTATIN	Merck & Co.	HMG-CoA Reductase Inhibitor	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1987-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Merck & Co. · 3 drugs in Mixed hyperlipidemia
AbbVie · 1 drug in Mixed hyperlipidemia
AstraZeneca · 1 drug in Mixed hyperlipidemia
Bayer · 1 drug in Mixed hyperlipidemia
Cedars-Sinai Medical Center · 1 drug in Mixed hyperlipidemia
Kowa Co · 1 drug in Mixed hyperlipidemia
Kowa Research Institute, Inc. · 1 drug in Mixed hyperlipidemia
MEDPOINTE PHARM HLC · 1 drug in Mixed hyperlipidemia
Medpointe Pharm Hlc · 1 drug in Mixed hyperlipidemia
NVP Healthcare · 1 drug in Mixed hyperlipidemia
Novartis · 1 drug in Mixed hyperlipidemia
Pfizer · 1 drug in Mixed hyperlipidemia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Mixed hyperlipidemia:

Cite this brief

Drug Landscape (2026). Mixed hyperlipidemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/mixed-hyperlipidemia. Accessed 2026-06-10.

Mixed hyperlipidemia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing